帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好，仅出现轻度胃肠道不良事件，并展现出有前景的活性，值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
BANF1 是头颈部鳞状细胞癌中与免疫浸润相关的新型预后生物标志物
英文原题：BANF1 is a novel prognostic biomarker linked to immune infiltration in head and neck squamous cell carcinoma.
查看英文原题
BANF1 is a novel prognostic biomarker linked to immune infiltration in head and neck squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
BANF1 可促进 HNSCC 患者的肿瘤进展。BANF1 作为评估预后的潜在生物标志物显示出巨大前景。
研究思路结论见上方概要
背景
屏障自整合因子1（BANF1）是一种丰富且广泛表达的出生后哺乳动物蛋白，在多种人类癌症中过表达，并能促进癌细胞增殖。然而，BANF1在头颈部鳞状细胞癌（HNSCC）预后中的作用仍不清楚。
方法
BANF1表达数据来自GEO和TCGA数据库。我们使用Cox回归和Kaplan-Meier曲线评估BANF1的预后潜力。通过京都基因与基因组百科全书（KEGG）和基因本体论（GO）富集分析研究BANF1相关基因的作用。此外，我们探讨了BANF1、药物敏感性和肿瘤免疫微环境之间的联系。最后，使用体外和体内功能实验探究BANF1对HNSCC肿瘤生长和转移的影响。
结果
BANF1在HNSCC中显著过表达，并与临床病理特征相关。根据生存分析，BANF1可与患者生存呈负相关，并可作为预后风险指标。化疗治疗的IC50值表明，BANF1高表达组对大多数抗肿瘤治疗更敏感。此外，在BANF1低表达组中观察到更高的TIDE评分，表明免疫检查点抑制剂治疗疗效下降。在功能上，当BANF1表达被敲低时，HNSCC细胞系的恶性生物学行为受到抑制。
展开英文摘要原文
BACKGROUND
Barrier-to-autointegration factor 1 (BANF1) is an abundant and ubiquitously expressed postnatal mammalian protein that is overexpressed in numerous human cancers and can promote cancer cell proliferation. However, the role of BANF1 in prognosis remains unclear in head and neck squamous cell carcinoma (HNSCC).
METHODS
BANF1 expression data were obtained from the GEO and TCGA databases. We used Cox regression and Kaplan-Meier curves to assess the prognostic potential of BANF1. The role of BANF1-related genes was investigated using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses. In addition, we explored the link between BANF1, drug sensitivity, and the tumor immune microenvironment. Finally, functional in vitro and in vivo assays were used to explore the effects of BANF1 on tumor growth and metastasis of HNSCC.
RESULTS
BANF1 was markedly overexpressed in HNSCC and was correlated with clinicopathological characteristics. According to survival analysis, BANF1 can be inversely correlated with patient survival and can act as a prognostic risk indicator. IC50 values for chemotherapeutic treatments indicated that the group with high BANF1 expression was more responsive to most antitumor treatments. Furthermore, higher TIDE scores were observed in the low BANF1 expression group, indicating a decline in the efficacy of immune checkpoint inhibitor therapy. Functionally, the malignant biological behavior of HNSCC cell lines was inhibited when BANF1 expression was knocked down.
CONCLUSION
BANF1 can promote tumor progression in patients with HNSCC. BANF1 shows great promise as a potential biomarker to assess the prognosis.
论文信息
- 作者
- He Y、Li H、Li J、Huang J、Liu R、Yao Y、Hu Y、Yang X
- 单位
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, China.China
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39439799 · DOI 10.3389/fimmu.2024.1465348
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →